Abstract: An ablation device and method for monitoring and controlling temperature, pressure and position of an ablation probe for precise destruction of unwanted one of nerve tissue and soft tissue. The ablation device includes a probe configured to generate pressure and temperature for ablating the unwanted soft tissue and nerve tissue The device can also include a monitoring device, an imaging device, and a computer system. The probe includes at least two prongs, the at least two prongs each including distal ends, the distal ends being configured to define, in combination, a probe geometry substantially matching an anatomical tissue geometry of the unwanted one of nerve tissue and soft tissue.

Abstract: A delivery system comprising a covering containing at least a first substance for release to a surgical site is provided. The covering includes an elongated containment portion having at least one compartment, wherein the covering retains the first substance for mixing with a second substance prior to delivery at a surgical site. The covering may be a single or multi compartment structure capable of retaining at least partially the mixture of the at least first and second substances until the covering is placed at the surgical site. The elongated containment portion of the covering includes a first end and second end opposite each other, wherein at least one end defines an access port configured to receive a device capable of delivering a second substance into the elongated containment portion for mixing with the first substance prior to or during the surgical procedure.

Abstract: Ablation kits useful for destroying nerve and soft tissue via a minimally invasive procedure to alleviate pain are provided. The device comprises a probe having an exterior and an interior. The exterior comprises a tip and the interior defines a passage having a filament and insulation disposed therein. The filament has an opening configured to release a pressurized material into the interior of the probe so as to cool the tip to a selected temperature to ablate nerve and/or soft tissue. A bone piercing instrument is provided that is configured to pierce bone so as to allow entry of the probe into the bone. Methods for ablating nerve and/or soft tissue utilizing the ablation devices are also provided.

Abstract: A surgical implant for blocking neural regrowth following a surgical procedure is provided. The implant comprises a press, such as, for example, a clip, having a first portion and a second portion. The second portion is rotatable with respect to the first portion. The first and second portions each having an inner surface configured for engagement with tissue, such as, for example, a denatured nerve. A method of use utilizing the surgical implant is also provided.

Abstract: A bone graft delivery device is provided comprising: a porous biodegradable graft body for inducing bone growth at a surgical site, the porous biodegradable graft body having demineralized bone matrix (DBM) fibers disposed within the porous biodegradable body, and DBM powder disposed adjacent to, on or in the DBM fibers, wherein the porous biodegradable graft body facilitates transfer of cells into and out of the porous biodegradable graft body to induce bone growth at the surgical site. Methods of making the device and using the device are also disclosed.

Abstract: A spinal implant is provided. The spinal implant includes a body extending between a proximal end and a distal end. The proximal end defines a notch configured for disposal of a first vertebra. The distal end includes a protrusion configured for disposal in a second vertebra. The proximal and distal ends are movable relative to one another between an unexpanded position in which the spinal implant is inserted between lamina and an expanded position in which the spinal implant is disposed between the lamina.

Abstract: Methods of making and osteoinductive compositions are provided. The method includes mixing isolated periosteum tissue with a demineralized bone matrix to form the osteoinductive composition. The periosteum tissue is isolated from the surface of large bones such as femur, tibia, humerus or a mixture thereof. The demineralized bone matrix can include a plurality of surface demineralized or fully demineralized bone fibers, bone chips, bone particles or mixtures thereof. In the osteoinductive composition the substantially isolated periosteum tissue is from about 0.5% wt. to about 10% wt. A method for repairing a bone defect is also provided. The method of treatment includes applying to the bone defect a substantially effective amount of a mixture of isolated periosteum tissue and demineralized bone matrix.

Abstract: Flowable compositions and methods are provided for delivering a therapeutic agent at or near a target tissue site beneath the skin of a patient, the flowable composition comprising (i) a solvent and (ii) an effective amount of the therapeutic agent, the flowable composition being capable of hardening to form a drug depot at a physiological temperature or as solvent contacts bodily fluid at or near the target tissue site, wherein the drug depot is capable of releasing the therapeutic agent over a period of at least one day and the target tissue site comprises at least one muscle, ligament, tendon, cartilage, spinal disc, spinal foraminal space near the spinal nerve root, facet or synovial joint, or spinal canal.

Abstract: Compositions and methods for augmenting bone formation by administering isolated human mesenchymal stem cells (hMSCs) within a matrix provided. By adding calcium and/or phosphate ions to the matrix, one may foster greater bone regeneration.

Abstract: Effective treatments of pain and/or inflammation from degenerative disc disease and/or facet joint are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a degenerative disc and/or facet joint, one can reduce, prevent or treat pain and/or inflammation caused by the degenerative disc disease and/or facet joint.

Abstract: Ablation devices useful for destroying nerve and soft tissue via a minimally invasive procedure to alleviate pain are provided. The device comprises a probe comprising an outer tube having an exterior surface comprising a tip and an interior surface that defines an internal passage. An inner tube is disposed within the outer tube and comprises an interior surface that defines an internal passage having a filament disposed therein. The filament has an opening configured to release a pressurized material into the interior surface of the probe so as to cool the exterior surface of the outer tube to a selected temperature. Disposal of the inner tube within the internal passage of the outer tube produces an air gap that surrounds the exterior surface of the inner tube, and the tip is configured for ablating nerve and/or soft tissue. Methods for ablating nerve and/or soft tissue utilizing the ablation devices are also provided.

Abstract: Improved medical devices and methods are provided that are implantable at or near a target tissue site beneath the skin of a patient, the medical device comprises an adhesive sheet having a region configured to receive a drug depot, the drug depot disposed within the region of the adhesive sheet and the drug depot having at least one surface configured to release a therapeutically effective amount of the drug over a period of at least one day, wherein the adhesive sheet limits movement of the medical device at or near the target tissue site. In some embodiments, the medical device provided can include an effective amount of at least one analgesic and/or at least one anti-inflammatory agent at or near a target site, and can reduce, prevent or treat inflammation and/or pain, particularly postoperative pain or orthopedic degenerative pathology pain.

Abstract: Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or treat sciatic pain and/or inflammation. In various embodiments, prevent transplant rejection for at least twenty-five days. In some embodiments, the pain relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Abstract: Ablation devices useful tor destroying nerve and soft tissue via a minimally invasive procedure to alleviate pain are provided. The device comprises a probe comprising an ulterior surface, that defines an internal passage and an exterior surface comprising a tip. The internal passage has a filament comprising an opening configured to release a pressurized material into the interior surface of the probe so as to cool the exterior surface of the probe to a selected temperature. A release instrument is provided comprising a sheath that comprises an exterior surface and an interior surface configured for engagement with the probe. The probe tip is configured for ablating nerve and/or soft tissue by forming an ice ball, and the release instrument is configured to release the probe tip from the ice ball. Methods for ablating nerve and/or soft tissue utilizing the ablation devices are also provided.

Abstract: Osteoconductive matrices and methods are provided that have one or more statins disposed therein. The matrices may be injected into a fracture site. The osteoconductive matrices provided allow for sustain release of the statin and facilitate bone formation and repair of the fracture site.

Abstract: A drug-eluting device comprising a drug-eluting matrix containing at least one elutable drug, a method of manufacturing a preformed drug-eluting device, and an implant kit comprising the same.

Abstract: Effective treatments of pain and/or inflammation from degenerative disc disease and/or facet joint are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a degenerative disc and/or facet joint, one can reduce, prevent or treat pain and/or inflammation caused by the degenerative disc disease and/or facet joint.

Abstract: Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment pain by inhibiting the NF?B family of transcription factors.

Abstract: The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.

Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.